Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study.

Biomol Biomed · 2023 · PMC10655877 · PMID 37289436

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Furthermore, median OS in the dose-escalation cohort showed a positive trend with 9.8 months compared with 6 months in the standard-dose group.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.